m (→Postdoctoral Scholar)
|Line 59:||Line 59:|
*Dr. Yong Wang, Ph.D. (2005-present)
*Dr. Yong Wang, Ph.D. (2005-present)
*Dr. Ashita Dhillon, Ph.D. (2006-present) (in conjunction with Linc
*Dr. Ashita Dhillon, Ph.D. (2006-present) (in conjunction with Linc 's laboratoryat Tufts Medical School)
Revision as of 13:50, 10 July 2007
- (9/15/06) Congratulations to Haoran for passing the chemical engineering's Ph.D. program's qualifying exam!
- (8/2/06) Congratulations to Janelle for successfully defending her thesis for an M.S. in chemical engineering!
Assistant Professor Blaine A. Pfeifer
2003 - American Cancer Society Postdoctoral Fellowship, Chemical Engineering, Massachusetts Institute of Technology
Advisor: Robert S. Langer (Institute Professor) (Langer Lab)
2002 - Ph.D., Chemical Engineering, Stanford University
Dissertation Advisor: Chaitan Khosla (Wells H. Rauser & Harold M. Petiprin Professor in the School of Engineering and Professor of Chemical Engineering, Chemistry, & Biochemistry)
1997 - B.S., Chemical Engineering, Colorado State University
- Wang Y*, Boghigian BA*, Pfeifer BA. Improving heterologous polyketide production in Escherichia coli by over-expression of an S-adenosylmethionine synthetase gene. 2007. Submitted.
- Parsa S, Pfeifer B. Engineering bacterial vectors for delivery of genes and proteins to antigen-presenting cells. Mol Pharm. 2007 Jan-Feb;4(1):4-17.
- Pfeifer BA, Burdick JA, Little SR, Langer R. Poly(ester-anhydride):poly(β-amino ester) micro- and nanospheres: DNA encapsulation and cellular transfection. Int J Pharm. 2005 Nov 4;304(1-2):210-9.
- Pfeifer BA, Burdick JA, Langer R. Formulation and surface modification of poly(ester-anhydride) micro- and nanospheres. Biomaterials. 2005 Jan;26(2):117-24.
- Pfeifer BA, Wang CC, Walsh CT, Khosla C. Biosynthesis of Yersiniabactin, a complex polyketide-nonribosomal peptide, using Escherichia coli as a heterologous host. Appl Environ Microbiol. 2003 Nov;69(11):6698-702.
- Kinoshita K, Pfeifer BA, Khosla C, Cane DE. Precursor-directed polyketide biosynthesis in Escherichia coli. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3701-4.
- Hu Z, Pfeifer BA, Chao E, Murli S, Kealey J, Carney JR, Ashley G, Khosla C, Hutchinson CR. A specific role of the Saccharopolyspora erythraea thioesterase II gene in the function of modular polyketide synthases. Microbiology. 2003 Aug;149(Pt 8):2213-25.
- Pfeifer B, Hu Z, Licari P, Khosla C. Process and metabolic strategies for improved production of scherichia coli-derived 6-deoxyerythronolide B. Appl Environ Microbiol. 2002 Jul;68(7):3287-92.
- Dayem LC, Carney JR, Santi DV, Pfeifer BA, Khosla C, Kealey JT. Metabolic engineering of a methylmalonyl-CoA mutase-epimerase pathway for complex polyketide biosynthesis in Escherichia coli. Biochemistry. 2002 Apr 23;41(16):5193-201.
- Lombo F, Pfeifer B, Leaf T, Ou S, Kim YS, Cane DE, Licari P, Khosla C. Enhancing the atom economy of polyketide biosynthetic processes through metabolic engineering. Biotechnol Prog. 2001 Jul-Aug;17(4):612-7.
- Pfeifer BA, Khosla C. Biosynthesis of polyketides in heterologous hosts. Microbiol Mol Biol Rev. 2001 Mar;65(1):106-18. Review.
- Pfeifer BA, Admiraal SJ, Gramajo H, Cane DE, Khosla C. Biosynthesis of complex polyketides in a metabolically engineered strain of E. coli. Science. 2001 Mar 2;291(5509):1790-2.
Research Interests, Areas, or Ongoing Projects
Our group takes a molecular and process engineering approach to generating therapeutic natural products. Our work is multidisciplinary with molecular biology, microbiology, analytical chemistry, and bacterial genetics supporting the development of microbial bioprocesses and products. The particular compounds and processes we strive to produce target diseases that include cancer, bacterial infections, and diabetes.
The common research theme in our lab is to find more efficient and economical ways to generate biological products. The approach is to transplant the genetic material responsible for an important therapeutic product into a convenient and process-friendly bacterial microorganism (such as Escherichia coli) for eventual product scale-up and development.
- The cellular and metabolic optimization for the production of the antibiotic erythromycin. Here, we are interested in optimizing the cellular biosynthetic process leading to large-scale process optimization.
- The production of new and established anticancer agents. This research aim seeks to generate potent anticancer agents through recombinant DNA technology. We are currently working towards the production of the following anti-cancer compounds through E. coli:
- Paclitaxel (Taxol)
Our research program emphasizes new and multiple disciplines to augment a traditional engineering education and embrace both chemical and biological engineering. Coupled with a group infrastructure that emphasizes commitment, teamwork, organization, creativity, and independence, our goal is to equip the student with the technical know-how and intellectual preparation to conduct and lead research.
- Dr. Yong Wang, Ph.D. (2005-present)
- Dr. Ashita Dhillon, Ph.D. (2006-present) (in conjunction with [Linc Sonenshein's laboratory] at Tufts Medical School)
- Guangquan Shi (Ph.D.) (2004-present)
- Haoran Zhang (Ph.D.) (2005-present)
- Saba Parsa (M.S.) (2006-present)
- Mike Pistorino (Ph.D.) (2007-present)
- Brett Boghigian (2005-present)
- Katie Rines (2007-present)
- Andre Loli (2007-present)
- Janelle Lavoie (M.S. 2006)